Sienna Biopharmaceuticals (SNNA) Sets New 52-Week Low at $1.93
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as $1.93 and last traded at $1.99, with a volume of 2336 shares changing hands. The stock had previously closed at $2.16.
Several equities analysts recently commented on SNNA shares. Zacks Investment Research downgraded Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. ValuEngine downgraded Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th.
The company has a debt-to-equity ratio of 1.13, a current ratio of 2.07 and a quick ratio of 2.07. The company has a market cap of $65.62 million, a P/E ratio of -0.57 and a beta of 3.64.
Several large investors have recently bought and sold shares of SNNA. Bank of New York Mellon Corp lifted its position in shares of Sienna Biopharmaceuticals by 18.1% during the third quarter. Bank of New York Mellon Corp now owns 43,627 shares of the company’s stock worth $647,000 after acquiring an additional 6,682 shares in the last quarter. BlackRock Inc. lifted its position in shares of Sienna Biopharmaceuticals by 3.0% during the third quarter. BlackRock Inc. now owns 1,040,257 shares of the company’s stock worth $15,417,000 after acquiring an additional 29,919 shares in the last quarter. FMR LLC lifted its position in shares of Sienna Biopharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 3,119,969 shares of the company’s stock worth $46,238,000 after acquiring an additional 10,109 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth $200,000. Finally, Jane Street Group LLC purchased a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth $182,000. Hedge funds and other institutional investors own 30.59% of the company’s stock.
About Sienna Biopharmaceuticals (NASDAQ:SNNA)
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Further Reading: Treasury Bonds
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.